Protagenic (PTIX) Exec Chair Armen Garo Buys 16,634 Shares

What Happened
Armen Garo H, Executive Chair, Principal Officer and Director of Protagenic Therapeutics (PTIX), made an open-market purchase of 16,634 shares at $0.59 per share on August 20, 2026, for a total cost of about $9,811. This was a direct purchase (transaction code P), which is a straightforward acquisition of common stock rather than a sale or derivative transaction.

Key Details

• Transaction date: 2026-08-20 (reported same day)
• Transaction type: Open-market purchase (Code: P)
• Price per share: $0.59; Shares acquired: 16,634; Total value: ~$9,811
• Shares owned after transaction: Not specified in the provided filing details
• Filing timeliness: Reported/Filed on 2026-08-20 (appears timely)
• SEC accession #: 0001493152-26-039537
• No 10b5-1 plan, tax withholding, or other special footnotes were indicated in the supplied summary

Context
Purchases by insiders are often viewed as more informative than sales because they represent direct capital put into the company; however, this transaction is relatively small in dollar terms (~$9.8k). The trade was a simple open-market buy — not an option exercise, award, or gift — and therefore reflects an outright addition of shares to the insider's holdings.